{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T11:48:29Z","timestamp":1768564109687,"version":"3.49.0"},"posted":{"date-parts":[[2023,8,15]]},"group-title":"Health Informatics","reference-count":38,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2023,8,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Statin-associated muscle symptoms (SAMS) contribute to the nonadherence to statin therapy. In a previous study, we successfully developed a pharmacological SAMS (PSAMS) phenotyping algorithm that distinguishes objective versus nocebo SAMS using structured and unstructured electronic health records (EHRs) data. Our aim in this paper was to develop a pharmacological SAMS risk stratification (PSAMS-RS) score using these same EHR data.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Method<\/jats:title>\n                  <jats:p>Using our PSAMS phenotyping algorithm, SAMS cases and controls were identified using University of Minnesota (UMN) Fairview EHR data. The statin user cohort was temporally divided into derivation (1\/1\/2010 to 12\/31\/2018) and validation (1\/1\/2019 to 12\/31\/2020) cohorts. First, from a feature set of 38 variables, a Least Absolute Shrinkage and Selection Operator (LASSO) regression model was fitted to identify important features for PSAMS cases and their coefficients. A PSAMS-RS score was calculated by multiplying these coefficients by 100 and then adding together for individual integer scores. The clinical utility of PSAMS-RS in stratifying PSAMS risk was assessed by comparing the hazard ratio (HR) between 4th vs 1st score quartile.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>PSAMS cases were identified in 1.9% (310\/16128) of the derivation and 1.5% (64\/4182) of the validation cohort. After fitting LASSO regression, 16 out of 38 clinical features were determined to be significant predictors for PSAMS risk. These factors are male gender, chronic pulmonary disease, neurological disease, tobacco use, renal disease, alcohol use, ACE inhibitors, polypharmacy, cerebrovascular disease, hypothyroidism, lymphoma, peripheral vascular disease, coronary artery disease and concurrent uses of fibrates, beta blockers or ezetimibe. After adjusting for statin intensity, patients in the PSAMS score 4th quartile had an over seven-fold (derivation) (HR, 7.1; 95% CI, 4.03-12.45) and six-fold (validation) (HR, 6.1; 95% CI, 2.15-17.45) higher hazard of developing PSAMS versus those in 1st score quartile.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The PSAMS-RS score can be a simple tool to stratify patients\u2019 risk of developing PSAMS after statin initiation which can facilitate clinician-guided preemptive measures that may prevent potential PSAMS-related statin non-adherence.<\/jats:p>\n                <\/jats:sec>","DOI":"10.1101\/2023.08.10.23293939","type":"posted-content","created":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T01:20:12Z","timestamp":1692148812000},"source":"Crossref","is-referenced-by-count":0,"title":["Development and validation of the pharmacological statin-associated muscle symptoms risk stratification (PSAMS-RS) score using real-world electronic health record data"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9381-6903","authenticated-orcid":false,"given":"Boguang","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pui Ying","family":"Yew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-Lin","family":"Chi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meijia","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matt","family":"Loth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8258-3585","authenticated-orcid":false,"given":"Rui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9541-7823","authenticated-orcid":false,"given":"Robert J.","family":"Straka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2023081903051223000_2023.08.10.23293939v1.1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.13044"},{"key":"2023081903051223000_2023.08.10.23293939v1.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2012.03.003"},{"key":"2023081903051223000_2023.08.10.23293939v1.3","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jacl.2022.09.001","article-title":"Assessment and management of statin-associated muscle symptoms (SAMS): A clinical perspective from the National Lipid Association","volume":"17","year":"2023","journal-title":"J. Clin. Lipidol"},{"key":"2023081903051223000_2023.08.10.23293939v1.4","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/cpt.526","article-title":"Development and validation of algorithms for the detection of statin myopathy signals from electronic medical records","volume":"101","year":"2017","journal-title":"Clin. Pharmacol. Ther"},{"key":"2023081903051223000_2023.08.10.23293939v1.5","first-page":"466","article-title":"Phenotyping Adverse Drug Reactions: Statin-Related Myotoxicity","volume":"2015","year":"2015","journal-title":"AMIA Jt Summits Transl Sci Proc"},{"key":"2023081903051223000_2023.08.10.23293939v1.6","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/jcpt.12063","article-title":"Development of a detection algorithm for statin-induced myopathy using electronic medical records","volume":"38","year":"2013","journal-title":"J. Clin. Pharm. Ther"},{"key":"2023081903051223000_2023.08.10.23293939v1.7","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.jacl.2016.05.002","article-title":"The nocebo effect in the context of statin intolerance","volume":"10","year":"2016","journal-title":"J. Clin. Lipidol"},{"key":"2023081903051223000_2023.08.10.23293939v1.8","doi-asserted-by":"publisher","DOI":"10.1101\/2023.05.04.23289523"},{"key":"2023081903051223000_2023.08.10.23293939v1.9","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-017-6723-4"},{"key":"2023081903051223000_2023.08.10.23293939v1.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.04.053"},{"key":"2023081903051223000_2023.08.10.23293939v1.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2010.02.026"},{"key":"2023081903051223000_2023.08.10.23293939v1.12","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2023-003765"},{"key":"2023081903051223000_2023.08.10.23293939v1.13","doi-asserted-by":"crossref","first-page":"579","DOI":"10.2217\/pgs.12.11","article-title":"Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutions","volume":"13","year":"2012","journal-title":"Pharmacogenomics"},{"key":"2023081903051223000_2023.08.10.23293939v1.14","doi-asserted-by":"publisher","DOI":"10.2165\/11319380-000000000-00000"},{"key":"2023081903051223000_2023.08.10.23293939v1.15","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.163.5.553"},{"key":"2023081903051223000_2023.08.10.23293939v1.16","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000456"},{"key":"2023081903051223000_2023.08.10.23293939v1.17","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaa188"},{"key":"2023081903051223000_2023.08.10.23293939v1.18","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/1472-6947-13-106","article-title":"Diabetic retinopathy risk prediction for fundus examination using sparse learning: a cross-sectional study","volume":"13","year":"2013","journal-title":"BMC Med. Inform. Decis. Mak"},{"key":"2023081903051223000_2023.08.10.23293939v1.19","doi-asserted-by":"crossref","first-page":"e0242730","DOI":"10.1371\/journal.pone.0242730","article-title":"A comparison of penalised regression methods for informing the selection of predictive markers","volume":"15","year":"2020","journal-title":"PLoS One"},{"key":"2023081903051223000_2023.08.10.23293939v1.20","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.2517-6161.1996.tb02080.x","article-title":"Regression Shrinkage and Selection via the Lasso","volume":"58","year":"1996","journal-title":"J. R. Stat. Soc. Series B Stat. Methodol"},{"key":"2023081903051223000_2023.08.10.23293939v1.21","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(02)00453-5"},{"key":"2023081903051223000_2023.08.10.23293939v1.22","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12875-022-01742-7","article-title":"Development and validation of a risk score to predict the frequent emergency house calls among older people who receive regular home visits","volume":"23","year":"2022","journal-title":"BMC Prim Care"},{"key":"2023081903051223000_2023.08.10.23293939v1.23","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1001\/jamainternmed.2020.2033","article-title":"Development and Validation of a Clinical Risk Score to Predict the Occurrence of Critical Illness in Hospitalized Patients With COVID-19","volume":"180","year":"2020","journal-title":"JAMA Intern. Med"},{"key":"2023081903051223000_2023.08.10.23293939v1.24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.9791"},{"key":"2023081903051223000_2023.08.10.23293939v1.25","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4"},{"key":"2023081903051223000_2023.08.10.23293939v1.26","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1093\/eurheartj\/ehaa574","article-title":"Independent risk factors for simvastatin-related myopathy and relevance to different types of muscle symptom","volume":"41","year":"2020","journal-title":"Eur. Heart J"},{"key":"2023081903051223000_2023.08.10.23293939v1.27","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.9736"},{"key":"2023081903051223000_2023.08.10.23293939v1.28","unstructured":"Varghese, D. , Ishida, C. & Koya, H. H. Polypharmacy. (StatPearls Publishing, 2022)."},{"key":"2023081903051223000_2023.08.10.23293939v1.29","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"2023081903051223000_2023.08.10.23293939v1.30","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199801000-00004"},{"key":"2023081903051223000_2023.08.10.23293939v1.31","doi-asserted-by":"publisher","DOI":"10.1097\/01.mlr.0000182534.19832.83"},{"key":"2023081903051223000_2023.08.10.23293939v1.32","unstructured":"Chou, R. et al. Table 1, Statin Dosing and ACC\/AHA Classification of Intensity. (Agency for Healthcare Research and Quality (US), 2022)."},{"key":"2023081903051223000_2023.08.10.23293939v1.33","doi-asserted-by":"publisher","DOI":"10.3310\/hta25590"},{"key":"2023081903051223000_2023.08.10.23293939v1.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.07.022"},{"key":"2023081903051223000_2023.08.10.23293939v1.35","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2012-302014"},{"key":"2023081903051223000_2023.08.10.23293939v1.36","doi-asserted-by":"crossref","first-page":"106188","DOI":"10.1016\/j.jstrokecerebrovasdis.2021.106188","article-title":"Temporal Validation of an Assessment Tool that Predicts a Possibility of Home Discharge for Patients with Acute Stroke","volume":"31","year":"2022","journal-title":"J. Stroke Cerebrovasc. Dis"},{"key":"2023081903051223000_2023.08.10.23293939v1.37","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-1120"},{"key":"2023081903051223000_2023.08.10.23293939v1.38","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/cpt.2557","article-title":"The Clinical Pharmacogenetics Implementation Consortium guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and statin-associated musculoskeletal symptoms","volume":"111","year":"2022","journal-title":"Clin. Pharmacol. Ther"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2023.08.10.23293939","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T19:38:54Z","timestamp":1768505934000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2023.08.10.23293939"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,15]]},"references-count":38,"URL":"https:\/\/doi.org\/10.1101\/2023.08.10.23293939","relation":{},"subject":[],"published":{"date-parts":[[2023,8,15]]},"subtype":"preprint"}}